Title: Clinical study of mololithic compound preparation of valsartan / amlodipine in the treatment of elderly patients with morning hypertension
Abstract: Objective To compare the efficacy of two kind of mololithic compound preparation of Valsartan /Amlodipine or Valsartan / Hydrochlorothiazide( HCTZ) in the treatment of elderly patients with morning blood pressure surge( MBPS),provide guidance and help for clinical treatment. Methods The selected 90 elderly patients with hypertention who treated or untreated were received single-agent valsartan 80 mg once every day,Then 58 patients with MBPS monitorized by using ambulatory blood pressure were enrolled and randomly assigned into two groups after single-agent treatment 4 weeks. In the treatment group,29 patients received a mololithic compound preparation of Valsartan / amlodipine once every day; In the control group,29 patients received another mololithic compound preparation of Valsartan / HCTZ once everyday. At baseline and after 4 weeks of treatment,24 hour average systolic blood pressure( SBP),24 hour average diastolic blood pressure( DBP),success rates of 24 hour blood pressure,the rates of MBPS control were observed. Results In two groups,after 4 weeks of mololithic compound preparation administration,24 hour average SBP,24 hour average DBP were reduced significantly( P 0. 05),and the reductions were greater in treatment group than control group( P 0. 05). In treatment group,higher proportion of patients reaching blood pressure target and morning blood pressure target was observed when compared with the control group( P 0. 05). Conclusion Both mololithic compound preparation Valsartan / Amlodipine and Valsartan / HCTZ are able to effectively manage elderly patients with MBPS. However,Valsartan / Amlodipine is superior to Valsartan / HCTZ in improving the achievement rate,controlling MBPS,and is more suitable for elderly patients with MBPS.
Publication Year: 2014
Publication Date: 2014-01-01
Language: en
Type: article
Access and Citation
AI Researcher Chatbot
Get quick answers to your questions about the article from our AI researcher chatbot